(Date:12/4/2008)...ican women using Carraguard had no decrease in inf...4 (HealthDay News) -- A microbicidal vaginal gel c...fection. , That,s the conclusion of a study tha...gative women at three sites in South Africa. , ...o gel and told to use one applicator of gel and a ...
(Date:12/4/2008)..., Dec. 4 Aurora Health Care is ram... D supplements. Aurora,s Care Management,Clinical...ucate all Aurora,caregivers about the benefits of...g evidence that higher Vitamin D levels may improv...porosis, certain muscle conditions and,seasonal d...
(Date:12/4/2008)...N, Dec. 4 The U.S. Gove...Development (USAID), is providing an additional $6...abwe. This assistance is in addition to the $4 mi...gram USAID is already implementing in Zimbabwe. ,... working alongside the international community to ...
(Date:12/4/2008)...cts similar to those seen with standard dose of da...c. 4 (HealthDay News) -- A high dose of the chemot...tients with previously untreated acute myeloid leu...red by the U.S. National Cancer Institute (NCI) sh...row. This study included 633 patients, aged 16 to ...
Breaking Medicine News(10 mins):Health News:Experimental Vaginal Gel Doesn't Ward Off HIV 2Health News:Aurora Health Care Urges All Wisconsin Residents to Take Vitamin D 2Health News:USAID Increases Assistance for Zimbabwe Cholera Outbreak 2Health News:Higher Chemo Drug Dose Prolongs Lives of Leukemia Patients 2(Date:12/2/2008)...RNewswire-USNewswire/ -- Researchers using functio... in the area of the brain,responsible for suppres... from,stress-related psychiatric disorders. Resul...nual meeting of the Radiological Society of North ... depression and other stress-related disorders,t...
(Date:12/2/2008)... 2 Horizon Therapeutics, Inc., a,...nounced that two pivotal,Phase 3 trials evaluatin...501,met all primary endpoints. HZT-501, a novel,...ining ibuprofen and famotidine, demonstrated a,st... of non-steroidal,anti-inflammatory drug (NSAID)-...
(Date:12/1/2008)... TargeGen has announced that an ora...ti-center, US-based clinical,trial of TG101348 in...duled at,the 2008 American Society of Hematology ...ion are as follows:, Title: A P... JAK2-Selective Inhibitor, ...
(Date:12/1/2008)...s still the best policy , , ROCHESTER, Min...from Mayo Clinic finds the use of the drug therapy...titis, an acute inflammation of the liver caused b... the study are published in the December issue of ... ). , , VIDEO ALERT: Additional audio and ...
Breaking Medicine Technology:Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 1Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 2Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 3Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 4Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 5Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 6Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 7Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 8Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 9Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 10Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 11Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 12Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 13Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 14Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 15Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 16Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 17Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 18Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 19Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 20Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 21Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 22Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 23Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 24Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 25Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 26Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 27Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 28Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 29Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 30Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 31Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 32Oncolytics Biotech Inc Announces 2008 First Quarter Results 5000 33Cadence Pharmaceuticals CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2008 4998 1Cadence Pharmaceuticals CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2008 4998 2ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing 1948 1ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing 1948 2ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing 1948 3ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing 1948 4Genetic Changes May Dictate Course of Acute Myeloid Leukemia 18089 1Genetic Changes May Dictate Course of Acute Myeloid Leukemia 18089 2Genetic Changes May Dictate Course of Acute Myeloid Leukemia 18089 3...tudy evaluating a clinically relevant model of,nor...gent capable,of abrogating the cytotoxic effect of...d OPTISOME(tm) agent was generally well,tolerated ...ent,profile similar to conventional vincristine , ...EWSWIRE) --,Hana Biosciences (Nasdaq:HNAB), a biop...
..., NJ – June 4, 2007 – Genta,Incorporat...sults,from a Phase 2 clinical trial of its markete..., plus rituximab (Rituxan®;,Genentech/IDEC) an...ctory non-Hodgkin’s lymphoma (NHL). The data...can Society of Clinical,Oncology (ASCO) in Chicago...
Other Medicine Technology:Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 2Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 3Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 4Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 5Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 2Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 3Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 4Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 5Non-sterile Silicone Tubing
Anodized aluminum. Durable and lightweight with built-in protection against rust. Security locks ensure against accidental opening. Silicone matting/V-strips and bumper guards hold instruments in pla
Diamond knife tray with silicone inserts to securely hold the diamond knife.
Size: 6 x 10 inches. Depth: 7 inches. Sterilizable plastic tray with silicone matting for supporting and protecting instruments.
Medicine Products: